Efficacy of metronomic vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance status

Basit Öğe Kaydı
dc.authoridDurak, Serdar/0000-0002-8175-9611
dc.authorwosidBilir, Cemil/A-2491-2017
dc.authorwosidk, l/T-8030-2019
dc.contributor.authorBilir, C.
dc.contributor.authorDurak, S.
dc.contributor.authorKizilkaya, B.
dc.contributor.authorHacibekiroglu, I.
dc.contributor.authorNayir, E.
dc.contributor.authorEngin, H.
dc.date.accessioned2024-06-12T11:08:27Z
dc.date.available2024-06-12T11:08:27Z
dc.date.issued2017
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground Metronomic chemotherapy-administration of low-dose chemotherapy-allows for a prolonged treatment duration and minimizes toxicity for unfit patients diagnosed with advanced non-small-cell lung cancer (NSCLC). Methods Oral metronomic vinorelbine at 30 mg thrice weekly was given to 35 chemotherapy-naive patients who were elderly and vulnerable to toxicity and who had been diagnosed with advanced nsclc. Results Median age in this male-predominant cohort (29: 6) was 76 years (range: 65-86 years). Histology was squamous cell carcinoma in 21 patients and adenocarcinoma in 14. There were no complete responses and 9 partial responses, for an overall response rate of 26%. Stable disease was seen in 15 patients (43%), and 11 patients (31%) had progressive disease. The 1-year survival rate was 34%, and the 2-year survival rate was 8%. The survival analysis showed a median progression-free survival duration of 4 months (range: 2-15 months) and an overall survival duration of 7 months (range: 3-24 months). Conclusions Metronomic vinorelbine had an acceptable efficacy and safety profile in elderly patients with multiple comorbidities who had been diagnosed with advanced nsclc. Metronomic vinorelbine could be a treatment option for elderly patients with poor performance status who are unfit for platinum-based chemotherapy and intravenous single-agent chemotherapy, and who are not candidates for combination modalities.en_US
dc.identifier.doi10.3747/co.24.3486
dc.identifier.endpageE204en_US
dc.identifier.issn1198-0052
dc.identifier.issue3en_US
dc.identifier.pmid28680287en_US
dc.identifier.scopus2-s2.0-85021315069en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpageE199en_US
dc.identifier.urihttps://doi.org/10.3747/co.24.3486
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22443
dc.identifier.volume24en_US
dc.identifier.wosWOS:000404547500006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMultimed Incen_US
dc.relation.ispartofCurrent Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMetronomic Vinorelbineen_US
dc.subjectNon-Small-Cell Lung Canceren_US
dc.subjectPoor Performance Statusen_US
dc.subjectRandomized Phase-Iien_US
dc.subjectOral Vinorelbineen_US
dc.subject1st-Line Treatmenten_US
dc.subjectPlus Cisplatinen_US
dc.subjectTrialen_US
dc.subjectNsclcen_US
dc.subjectChemotherapyen_US
dc.titleEfficacy of metronomic vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance statusen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu